Literature DB >> 17848663

Cancer killer may be "silent" no more.

Renee Twombly.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 17848663     DOI: 10.1093/jnci/djm163

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  10 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

2.  Predictive value of symptoms for early detection of ovarian cancer.

Authors:  Mary Anne Rossing; Kristine G Wicklund; Kara L Cushing-Haugen; Noel S Weiss
Journal:  J Natl Cancer Inst       Date:  2010-01-28       Impact factor: 13.506

Review 3.  Current and future applications of magnetic resonance imaging (MRI) to breast and ovarian cancer patient management.

Authors:  Jim Klostergaard; Kenia Parga; Raphael G Raptis
Journal:  P R Health Sci J       Date:  2010-09       Impact factor: 0.705

Review 4.  Epidemiological and genetic factors associated with ovarian cancer.

Authors:  Monica R McLemore; Christine Miaskowski; Bradley E Aouizerat; Lee-May Chen; Marylin J Dodd
Journal:  Cancer Nurs       Date:  2009 Jul-Aug       Impact factor: 2.592

5.  Ovarian cancer pathogenesis: a model in evolution.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  J Oncol       Date:  2009-09-06       Impact factor: 4.375

Review 6.  Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.

Authors:  Rekha Wuntakal; Srividya Seshadri; Ana Montes; Geoff Lane
Journal:  Cochrane Database Syst Rev       Date:  2016-06-29

Review 7.  Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.

Authors:  Aramide O Lawal; Alfred Musekiwa; Liesl Grobler
Journal:  Cochrane Database Syst Rev       Date:  2013-06-06

8.  Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro.

Authors:  Shanshan Hong; Xiaoyan Zhang; Jun Chen; Jiabing Zhou; Yufang Zheng; Congjian Xu
Journal:  J Ovarian Res       Date:  2013-11-20       Impact factor: 4.234

9.  The double-edged sword of ovarian cancer information for women at increased risk who have previously taken part in screening.

Authors:  Stephanie Smits; Jacky Boivin; Usha Menon; Kate Brain
Journal:  Ecancermedicalscience       Date:  2016-06-30

10.  Symptoms and risk factors of ovarian cancer: a survey in primary care.

Authors:  Ketan Gajjar; Gemma Ogden; M I Mujahid; Khalil Razvi
Journal:  ISRN Obstet Gynecol       Date:  2012-08-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.